Immunization (HIV Prevention)

5,000 Volunteers Inoculated in U.S. Trial of HIV Vaccine

Published in AIDS Weekly, October 25th, 1999

VaxGen, Inc., Brisbane, California, announced that it has inoculated more than 5,000 volunteers, completing enrollment in the United States portion of the North American trial of AIDSVAX, a vaccine designed to prevent infection by HIV.

Additionally, the company announced it has completed a private placement of common stock resulting in proceeds of $25 million to the company, enabling the company to expand its vaccine research to develop HIV vaccines for worldwide eradication of AIDS.

The inoculation of more than 5,000 volunteers in the study, the first-ever Phase III clinical trial of a preventive HIV vaccine, took place at 56 clinics in the U.S....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1999-10-25)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry